Investor resources

Why Invest?

Investment Highlights

cold laser therapy technology
Clinically Proven

Theralase®’s patented lead PDC (TLD-1433) has successfully completed a Phase Ib Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study demonstrating strong safety and a 67% Complete Response (“CR”) rate for patients treated at the therapeutic dose.

In-progress pivotal Phase II NMIBC clinical study.

cold laser therapy milestones
Scientifically Researched

Patented light-activated Photo Dynamic Compounds ("PDCs") have been scientifically and preclinically researched for 10+ years to optimize their ability to destroy cancer, bacteria and viruses.

Over 10+ peer reviewed published research publications.

laser therapy for pain clinical stage
Extensive Pipeline

Lead
NMIBC

Under Development
Non-Small Cell Lung Cancer (“NSCLC”)
Vaccine for various enveloped viruses

Granted FDA Fast Track Designation in November 2020 for Phase II Clinical Study

laser therapy theralase management team
Experienced Team

Strong management team with extensive pharmaceutical research, development, manufacturing, commercialization and clinical research experience.

Partnered with leading scientific and clinical researchers from renowned research hospitals to develop cutting-edge technologies to destroy cancer and eliminate pain.

cold laser therapy theralase
Intellectual Property

24 issued patents for its PDC technology in the United States, Canada, China, Russia, Brazil, India and Europe

28 patents pending

PRESS RELEASES

Corporate Presentation

DOWNLOAD
theralase testimonials

Fact Sheet

DOWNLOAD
clinical research PDT

Quarterly Newsletters

BROWSE
about theralase

Financial Filings

BROWSE
investor information

Press Releases

BROWSE

Contact Information

Transfer Agent:

TMX Equity Transfer Services Inc.

100 Adelaide Streety West, Suite 301,
Toronto, Ontario
M5H 1S3, CANADA

Work: 416-361-0930
Website: www.tsxtrust.com 

Auditor:

Richter LLP

181 Bay Street, Suite 3510
Bay Wellington Tower
Toronto, Ontario
M5J 2T3, CANADA

Work: 416-488-2345
Fax: 416-488-3765
Web: www.richter.ca

Chief Financial Officer/Investor Relations

Kristina Hachey, CPA

Theralase Technologies Inc.

41 Hollinger Road,
Toronto, Ontario
M4B 3G4, CANADA 

Investor Information

Data last updated on April 22, 2022

Theralase® Inc. is a subsidiary of Theralase® Technologies Inc., and is publicly traded on the
  • TSX Venture Exchange (TSXV: TLT)
  • Over-The-Counter Exchange (OTCQB: TLTFF)
Number of common shares outstanding

Share Price: C$0.305

Warrants: 67,768,615

Shares Outstanding: 204,425,875

Stock Options: 13,460,000

Fully Diluted: 285,654,490

For Investor Relations please contact: Investor Information Theralase®

Our Partners

As part of our continuing mission to design, develop, and manufacture cutting-edge laser technologies, Theralase® has partnered with individuals and groups at the following institutions and organizations.

University Health Network
Virginia Tech
nova scotia health authority
curc
McGill University
nova scotia health authority
university of manitoba
Virginia urology
midlantic urology
urology associates
london health science
phac